$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Sepsis still remains the leading cause of death on non-cardiac intensive care units (ICU) with mortality rates of ≈ 30 - 50%1,2,3. A hallmark of severe sepsis and septic shock is the acute kidney injury that causes a further increase of mortality rate when it is associated with distant organ dysfunction such as cardiac and respiratory failure4,5,6. The overall incidence of AKI in ICU patients varies from 20 to 50%7. Despite the pivotal role of AKI regarding outcome and mortality in sepsis the underlying pathomechanism is still poorly understood.
Overall there are the 3 major components: inflammation, toxic injury, and hemodynamic changes that contribute to AKI development7. Hemodynamic changes encompass reduced renal blood flow (RBF) and global or regional renal ischemia. Here, it has to be considered that sepsis can also cause an impairment of renal microcirculation due to systemic hypotension and/or endothelial barrier disruption8. Therefore, the study of septic AKI should always include hemodynamic monitoring. Recent in vivo studies about AKI used mostly animal models such as renal ischemia-reperfusion injury or bilateral nephrectomy. These studies usually showed a lack of hemodynamic monitoring and intensive care.
The investigation of potential new pathomechanisms and therapies of septic AKI requires an in vivo model with a defined septic focus, an intensive care setup, a predictable outcome and an organ injury9,10,11,12. Here, we describe an innovative rodent model for septic AKI that meets the requirements mentioned before. Septic AKI is induced by standardized colon ascendens stent peritonitis (sCASP). The used sCASP model causes an abdominal sepsis by an intestinal fecal leakage leading to bacterial invasion and multi organ failure13. It has been shown that pathophysiological changes after CASP are similar to those in human sepsis and thus CASP represents a clinically relevant model in sepsis research11,14.
Furthermore, an intensive care (ICU) setup that comprises an advanced hemodynamic monitoring and ICU therapy is established in the experimental protocol. The ICU setup enables fluid resuscitation, analgesia application intravenously and repetitive blood gas analysis. The kidney function is evaluated by measurement of standard values such as creatinine and by inulin- and p-aminohippuric-acid-(PAH) clearance. Additional information is delivered by pathohistological scores of harvested tissue and organs at the end of the experiment. The sCASP model to induce septic AKI is already evaluated and revealed new insights in renal pathology15. Further application of this protocol presented below might help to refine the understanding of septic AKI.